| Name | Title | Contact Details |
|---|---|---|
Sarita Jain |
Senior Director, External R&D | Profile |
Aaron Cox |
Executive Vice President of Finance | Profile |
Paul Hoelscher |
Executive Vice President and Chief Financial Officer | Profile |
Lindsay Meyer |
Associate Director, Benefits and Wellness | Profile |
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Anadys Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Pinnacle Pharmaceutics Ltd is a Whitby, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
WellSpring Pharmaceutical Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette`s Disorder.